老年非瓣膜性心房颤动患者口服抗凝治疗的研究进展

葛 泽峰¹, 贺 利平²
1、内蒙古医科大学
2、内蒙古自治区人民医院

摘要

目的：心房颤动（Atrial Fibrillation ，AF) 是临床上常见的一种室上性快速性心律失常，尤其是在老年群体，
往往是 AF 发作甚至出现并发症才匆忙就医，目前为止，AF 的治疗策略分为三个方面，抗凝、控制心室率及转复窦性心律，
本研究旨在探讨老年非瓣膜性 AF 患者口服抗凝治疗的研究进展，以期为老年非瓣膜性 AF 患者的抗凝治疗侧重提供参考。

关键词

心房颤动；抗凝；老年；综述

参考

[1] Mensah G A, Roth G A, Fuster V. The Global Burden of Cardiovascular Diseases and Risk Factors: 2020 and Beyond[J]. J Am Coll Cardiol, 2019,74(20):2529-2532.

[2] Elliott A D, Middeldorp M E, Van Gelder I C, et al. Epidemiology and modifiable risk factors for atrial fibrillation[J]. Nat Rev Cardiol, 2023,20(6):404-417.

[3] Andrade J, Khairy P, Dobrev D, et al. The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms[J]. Circ Res, 2014,114(9):1453-1468.

[4] Bauersachs R M, Herold J. Oral Anticoagulation in the Elderly and Frail[J]. Hamostaseologie, 2020,40(1):74-83.

[5] 丁健操 , 辛延国 , 邢云利 , 等 . 老年非瓣膜性心房颤动患者抗凝治疗现状及其影响因素 [J]. 中华老年心脑血管病杂志 ,2022,24(11):1139-1142.

[6] Stacy Z A, Richter S K. Direct oral anticoagulants for stroke prevention in atrial fibrillation: treatment outcomes and dosing in special populations[J]. Ther Adv Cardiovasc Dis, 2018,12(9):247-262.

[7] Cleland J G, Coletta A P, Nikitin N, et al. Update of clinical trials from the American College of Cardiology 2003. EPHESUS, SPORTIF-III, ASCOT, COMPANION, UK-PACE and T-wave alternans[J]. Eur J Heart Fail, 2003,5(3):391-398.

[8] van der Wall S J, Lip G, Teutsch C, et al. Low bleeding and thromboembolic risk with continued dabigatran during cardiovascular interventions: the GLORIA-AF study[J]. Eur J Intern Med, 2021,91:75-80.

[9] Thomas T F, Ganetsky V, Spinler S A. Rivaroxaban: an oral factor Xa inhibitor[J]. Clin Ther, 2013,35(1):4-27.

[10] Lau W, Torre C O, Man K, et al. Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation : A Multinational Population-Based Cohort Study[J]. Ann Intern Med, 2022,175(11):1515-1524.

[11] Okumura K, Akao M, Yoshida T, et al. Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation[J]. N Engl J Med, 2020,383(18):1735-1745.

[12] Rutherford O W, Jonasson C, Ghanima W, et al. Effectiveness and safety of oral anticoagulants in elderly patients with atrial fibrillation[J]. Heart, 2022,108(5):345-352

[13] Sepehri S A, Dagres N, Hindricks G. [2020 ESC guidelines on atrial fibrillation : Summary of the most relevant recommendations and innovations][J]. Herz, 2021,46(1):28-37.

[14] Hohnloser S H, Camm J, Cappato R, et al. Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial[J]. Eur Heart J, 2019,40(36):3013-3021.